Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters

This report evaluated long-term changes in clinical severity and laboratory parameters in 3 adult patients with severe recalcitrant atopic dermatitis (AD) who were treated with intramuscular injections of 50 mg of autologous immunoglobulin G (IgG) twice a week for 4 weeks (autologous immunoglobulin therapy, AIGT) and followed up for more than 2 years after the treatment. We observed the following 4 major findings in these 3 patients during the long-term follow-up after AIGT. (1) Two of the 3 patients showed a long-term clinical improvement for more than 36 weeks after AIGT with a maximum decrease in clinical severity score greater than 80% from baseline. (2) These 2 patients also showed long-term decreases in serum total IgE concentrations and peripheral blood eosinophil count for more than 36 weeks after AIGT with a maximum decrease in the two laboratory parameters of allergic inflammatory greater than 70% from baseline. (3) No significant side effect was observed during the 2 years of follow-up period after the AIGT in all 3 patients. (4) Serum levels of IgG anti-idiotype antibodies to the F(ab')2 fragment of autologous IgG administered for the treatment were not significantly changed after AIGT in all 3 patients. These findings suggest that AIGT has long-term favorable effects on both clinical severity and laboratory parameters in selected patients with severe recalcitrant AD. Further studies are required to evaluate the clinical usefulness and therapeutic mechanism of AIGT for AD.

Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis

PURPOSE: The clinical usefulness of subcutaneous allergen immunotherapy (SCIT) in the treatment of atopic dermatitis (AD) is still controversial. We analyzed the clinical efficacy of SCIT in patients with AD and the clinical characteristics of patients showing a favorable clinical response to the treatment. MATERIALS AND METHODS: Two hundred and fifty one patients with AD sensitized to house dust mite (HDM) were treated by SCIT using HDM extract. The clinical severity of AD was measured using the standardized clinical severity scoring system for AD (SCORAD) at baseline and 12 months. A favorable clinical response to SCIT was defined as a decrease in SCORAD value at 12 months greater than 50% compared to baseline value. Severe AD was defined as a baseline SCORAD value above 50. RESULTS: A favorable clinical response to SCIT was observed in 73.6% of patients. The proportion of patients showing a favorable clinical response to SCIT was significantly higher in patients with severe AD (90.6%) than patients with mild to moderated AD (63.7%) (p<0.001). Patients with severe AD showing a favorable clinical response had a significantly shorter duration of AD (12.3±8.5 years; mean±SD) than patients with severe AD showing no significant clinical response (20.6±10.9 years) (p<0.05) at baseline. CONCLUSION: SCIT could be a clinically useful therapeutic option for patients with severe AD sensitized to HDM. Early initiation of SCIT might provide a favorable clinical outcome in patients with severe AD sensitized to HDM.

Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis

PURPOSE: The clinical usefulness of subcutaneous allergen immunotherapy (SCIT) in the treatment of atopic dermatitis (AD) is still controversial. We analyzed the clinical efficacy of SCIT in patients with AD and the clinical characteristics of patients showing a favorable clinical response to the treatment. MATERIALS AND METHODS: Two hundred and fifty one patients with AD sensitized to house dust mite (HDM) were treated by SCIT using HDM extract. The clinical severity of AD was measured using the standardized clinical severity scoring system for AD (SCORAD) at baseline and 12 months. A favorable clinical response to SCIT was defined as a decrease in SCORAD value at 12 months greater than 50% compared to baseline value. Severe AD was defined as a baseline SCORAD value above 50. RESULTS: A favorable clinical response to SCIT was observed in 73.6% of patients. The proportion of patients showing a favorable clinical response to SCIT was significantly higher in patients with severe AD (90.6%) than patients with mild to moderated AD (63.7%) (p<0.001). Patients with severe AD showing a favorable clinical response had a significantly shorter duration of AD (12.3±8.5 years; mean±SD) than patients with severe AD showing no significant clinical response (20.6±10.9 years) (p<0.05) at baseline. CONCLUSION: SCIT could be a clinically useful therapeutic option for patients with severe AD sensitized to HDM. Early initiation of SCIT might provide a favorable clinical outcome in patients with severe AD sensitized to HDM.

Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report

The management of severe recalcitrant atopic dermatitis (AD) is a challenging issue for clinicians and patients. We hypothesized that repeated intramuscular injections of autologous immunoglobulin (autologous immunoglobulin therapy: AIGT) might induce clinical improvements in patients with AD by stimulation of the active immune response to antigen-binding-site of pathogenic antibodies. We tried AIGT in 3 adult patients with severe recalcitrant AD whose clinical conditions could not be effectively controlled by medical treatments (including oral cyclosporine) for more than 2 years. Autologous immunoglobulin was purified from the autologous plasma by affinity chromatography using Protein A. The patients were treated by an intramuscular injection of 50 mg of autologous immunoglobulin twice a week for 4 weeks. A clinical severity score of AD (SCORAD value) showed a decrease greater than 30% at 8 weeks after the initiation of AIGT compared with the baseline before the initiation of AIGT in all 3 patients with severe recalcitrant AD. No significant side effects from treatment were observed. Further studies with larger numbers of patients are required to evaluate the clinical usefulness of AIGT for AD.

Fall Risk Nursing Assessment according to the International Classification of Functioning, Disability, and Health / 대한의료정보학회지

OBJECTIVE: The International Classification of Function, Disability and Health (ICF) was designed to provide a common language by describing the function and disability of clients for health care professionals. The purpose of this paper is to introduce the International Classification of Function, Disability and Health (ICF) in nursing and investigate its applicability in fall risk assessment. METHODS: The Fall risk assessment system using the International Classification of Function, Disability and Health (ICF) is based on the Downton fall risk assessment tool which is most commonly used to assess the risk of falls across populations in any health care setting. To develop system, we used NetBeans 5.0 within JAVA SE Development Kit 1.4.2 (JDK 1.4.2) and Microsoft Access 2003 database was used for the information storage. RESULT: The International Classification of Function, Disability and Health (ICF) items can cover all items of the Downton fall risk assessment tool except for medication because there is no medication related items in the International Classification of Function, Disability and Health (ICF). We mapped patient's sensory deficit, mental state, and gait state in the Downton fall risk assessment with sensory function & pain, mental function, and mobility in the International Classification of Function, Disability and Health (ICF) respectively. We also adapted the qualifier to measure the degree of impairment of patients in terms of performance and capacity. CONCLUSION: Using the International Classification of Function, Disability and Health (ICF), nurses can assess functional and environmental factors of fall risk in more detail. This study proved the applicability of the International Classification of the Function, Disability and Health (ICF) in the nursing practice. Using the system we developed, nurses can better communicate with other healthcare specialists in the area of fall risk. We suggest further studies that are applying the International Classification of Function, Disability and Health (ICF) in other areas of the nursing practice to more clearly describe the status of patients.

HL7 Development Framework based on Object-oriented Analysis & a Design for Chemotherapy Order System / 대한의료정보학회지

OBJECTIVE: This study proposes a hospital information system through the design and actualization of the Health Level 7 Development Framework (HDF) as a medical standard data model to sharing medical records between different hospital systems. The Health Level 7 Development Framework is a technique designed to capture domain expertise in a manner that it to be structured to create and validate models, which are subsequently translated into messages. METHODS: The process used Health Level 7 Development Framework methodology with Health Level 7 tools. RESULTS: We drew diagrams for each steps of the Health Level 7 Development Framework and an Extensible Markup Language (XML) schema for chemotherapy order system. CONCLUSION: This study applied Health Level 7 Development Framework methodology to practice. It is a good reference for the hospital information system (HIS) and enables information sharing among healthcare institutions.

A STUDY ON GEOMETRIC COMPARISON OF FOUR INTERCHANGEABLE IMPLANT PROSTHETIC RETAINING SCREWS AND MEASUREMENT OF LOOSENING TORGUE / 대한치과보철학회지

Since the concept of osseointegration was introduced by Branemark of Sweden, dental implants have been used for various dental prosthetic treatments. The survival rate of dental implant is likely to be closely related to the total biomechanical role of each component of implant system. The use of interchangeable component is very attractive for dental practitioners because such an approach would save treatment cost, flexibility of prosthetic treatment options as well as conveniences. Therefore, the use of interchangeable implant system has been increasing without scientific assessment of safety and efficacy of various interchangeable implant system. The purpose of this study, therefore, were to compare the geometric characteristic of four interchangeable dental implant screws and the loosening torque of these screws. Four types of dental implant screws tested in this study were Nobelpharma, 3i, Impla-med, Restore. Four screws each of the test specimens were subjected for scanning electron microscopic examinations under the same condition and a 35x magnified standard SEM picture was objected from each test specimen using JSM-5200 scanning microscope. From each of the SEM pictures, eight parameters, i.e., diameter of screw head, screw length, thread pitch, major diameter, neck diameter, neck length, crest width and root width were determined using a caliper. The measurement for each parameters were then corrected for their magnification factor. The loosening torque were also determined by using a torque gauge. All of the measurements were statistically analyzed by ANOVA test and multiple range test. Statistical significance was set in advance at the probability level of less than 0.05. All analyses were done with SPSS software for the personal computer. The conclusion obtained from this studies were summarized as the following; 1. No statistically significances were noted in the thread pitch, and crest width in the four screws, and in the case of major diameter, the Impla-med screw was significantly smaller than the other three screws (p<0.05). Therefore, four implant bolts could be physically inserted in a abutment nuts. 2. The diameter of screw head was decreased in the order of Restore, 3i, Nobelpharma, Impla-med screws and the length of screws were decreased in the order of 3i, Restore, Nobelpharma and Impla-med. The diameter of neck was decreased in the order of Impla-med, Restore, Nobelpharma, 3i screws. The differences of each of these parameters were statistically significant (p<0.05). The width of root of screws were decreased in the order of Nobelpharma, Impla-med, Restore and 3i. The differences among Nobelpharma and Impla-med, Restore and 3i were statistically significant (p<0.05). 3. When the screws were loosening 1, 3, 4 and 5 times, the loosening torque for Impla-med and 3i screws were significantly higher than that of Nobelpharma or Restore screws (p<0.05). However, when statistically smaller than that of 3i, Restore or Nobelpharma screws (p<0.05).